Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 13/20 | 0.58 |
| ▸ | BCHE | P06276 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
| ▸ | SELP | P16109 | 1/20 | 0.55 |
| ▸ | SELE | P16581 | 1/20 | 0.55 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.53 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.52 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108018 | 0.85 | BCHE (0.63) | NLRP3BCHEACHESELPSELE | |
| SCHEMBL4423340 | 0.83 | EPHX2 (0.71) | NLRP3SELPSELE | |
| SCHEMBL5106834 | 0.82 | NLRP3 (0.62) | NLRP3 | |
| SCHEMBL5102413 | 0.82 | GAA (0.66) | NLRP3 | |
| SCHEMBL5114611 | 0.82 | NLRP3 (0.74) | NLRP3 | |
| SCHEMBL5102596 | 0.81 | MEN1 (0.64) | NLRP3SELPSELE | |
| SCHEMBL4423342 | 0.80 | NLRP3 (0.75) | NLRP3 | |
| SCHEMBL19427518 | 0.80 | BCHE (0.64) | NLRP3BCHEACHESELPSELE | |
| SCHEMBL29520161 | 0.80 | NLRP3 (0.75) | NLRP3 | |
| SCHEMBL13984317 | 0.79 | ERCC1 (0.60) | ERCC1ERCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003101927-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | PROTEOTECH, INC. (US) | 2003-12-11 | — | — | WO | disclosed |